CRVS Corvus Pharmaceuticals Inc

Price (delayed)

$2.06

Market cap

$87.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.02

Enterprise value

$30.26M

Highlights
The EPS has soared by 99% YoY and by 80% QoQ
Corvus Pharmaceuticals's equity has surged by 90% YoY and by 2.1% QoQ
Corvus Pharmaceuticals's net income has surged by 87% YoY but it has decreased by 25% QoQ

Key stats

What are the main financial stats of CRVS
Market
Shares outstanding
42.42M
Market cap
$87.39M
Enterprise value
$30.26M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$5.78M
EBITDA
-$5.23M
Free cash flow
-$37.45M
Per share
EPS
-$0.02
Free cash flow per share
-$0.89
Book value per share
$2.52
Revenue per share
$0
TBVPS
$2.59
Balance sheet
Total assets
$109.39M
Total liabilities
$12.99M
Debt
$1.78M
Equity
$96.4M
Working capital
$56.76M
Liquidity
Debt to equity
0.02
Current ratio
5.59
Quick ratio
5.38
Net debt/EBITDA
10.92
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-6.4%
Return on equity
-7.6%
Return on invested capital
-13.2%
Return on capital employed
-6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRVS stock price

How has the Corvus Pharmaceuticals stock price performed over time
Intraday
5.1%
1 week
-4.63%
1 month
-23.99%
1 year
-50.36%
YTD
-42.13%
QTD
-22.85%

Financial performance

How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.5M
Net income
-$5.78M
Gross margin
N/A
Net margin
N/A
Corvus Pharmaceuticals's net income has surged by 87% YoY but it has decreased by 25% QoQ
The operating income rose by 10% year-on-year

Growth

What is Corvus Pharmaceuticals's growth rate over time

Valuation

What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 99% YoY and by 80% QoQ
Corvus Pharmaceuticals's equity has surged by 90% YoY and by 2.1% QoQ
The price to book (P/B) is 59% lower than the 5-year quarterly average of 1.9 and 51% lower than the last 4 quarters average of 1.6

Efficiency

How efficient is Corvus Pharmaceuticals business performance
The company's return on assets has surged by 89% YoY but it fell by 8% QoQ
The ROE has soared by 89% year-on-year but it is down by 7% since the previous quarter
Corvus Pharmaceuticals's return on invested capital has surged by 84% YoY but it has decreased by 21% QoQ

Dividends

What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRVS.

Financial health

How did Corvus Pharmaceuticals financials performed over time
The total assets has soared by 70% YoY
CRVS's current ratio is up by 13% from the previous quarter and by 7% YoY
The debt is 98% less than the equity
Corvus Pharmaceuticals's equity has surged by 90% YoY and by 2.1% QoQ
The debt to equity has dropped by 60% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.